Upstream Strategies in Vaccine Manufacturing

From Cell Line to Scale-Up: Upstream Strategies in Vaccine Manufacturing - An Introduction In the rapidly evolving field of vaccine production, continuous improvement is essential to meet the growing global demand for effective and safe vaccines. The need for optimization in cell culture processes is critical, as it impacts the efficiency and scalability of vaccine manufacturing. This webinar addresses these needs by exploring the latest advancements and best practices in cell culture for viral vaccine production, providing valuable insights for professionals striving to enhance their production capabilities. Join us for an insightful presentation on the essentials of cell culture for vaccine production. This session will provide an educational overview of the latest advancements in vaccine technology. Our speaker, Anna-Barbara Hachmann, PhD, will share her expertise on optimizing cell culture conditions, including process intensification and perfusion techniques, which are crucial for efficient vaccine production. Karen Einsfeldt, Field Applications Specialist from Thermo Fisher Scientific, will follow Prof. Genzel’s presentation with an overview of the media solutions and field application support provided by Thermo Fisher. This comprehensive session aims to equip scientists and professionals in biopharma with the knowledge needed to enhance their vaccine production processes. Meeting the growing global demand for safe and effective vaccines requires continuous improvements, therefore optimizing cell culture processes is key to improving efficiency and scalability. In this webinar, Dr. Anna-Barbara Hachmann will discuss strategies such as process intensification and perfusion to optimize upstream conditions. Karen Einsfeldt will then outline media solutions and application support to enhance consistency and performance. This webinar delivers practical insights and proven approaches to streamline workflows, reduce bottlenecks and strengthen vaccine production capabilities from early development through commercial scale.